ฝึกพูดภาษาอังกฤษด้วยเทคนิค Shadowing จากวิดีโอ: Genetics of Hypertrophic Cardiomyopathy

เลือกโหมดฝึก

แต่ละโหมดจะเปิดห้องฝึกแบบเต็มจอ

164 ประโยค
หากประโยคสั้นหรือยาวเกินไป กดที่ Edit เพื่อปรับแก้
1
I would very much like to thank the organizers for the opportunity to present to this Asia -Pacific Cardiovascular Conference.
2
I am pleased to discuss hypertrophic cardiomyopathy.
3
I am a heart failure heart transplant cardiologist.
4
I do direct a division of human genetics at The Ohio State University.
5
I have no conflicts and no disclosures.
6
So these are the classic phenotypes of cardiomyopathy has shown dilated, hypertrophic, and ARVC.
7
And I will juxtapose dilated with hypertrophic cardiomyopathy.
8
We've really learned a lot over the last 20 to 30 years about how both types of cardiomyopathies emerged.
9
So the conceptual basis, of course, for hypertrophic cardiomyopathy started in the 1990s with the discovery of hypertrophic cardiomyopathy genes.
10
First, of course, was MYH7 beta -myosin heavy chain, and then MYBPC3 or myosin binding protein C3,
11
then the troponins and tropomyosin.
12
And this picture shows both thick and thin filaments,
13
and HCM is really a genetic disease of both thick and thin filaments as shown here.
14
In 2000s then, the focus was more so on gene
15
and phenotype correlations with more attention to additional genes and also more rare variants.
16
And then in the 2010s, the aggregation of studies with new registries, as shown here, the HCM registries,
17
and also the SHARE registry.
18
And then more sophisticated gene curation efforts,
19
ClinGen was the next with the integration of GWAS with common variant and sequence and rare variant data for polygenic risk scores,
20
and I'll comment on that below.
21
So the conceptual basis of cardiomyopathy also took cellular and biology of physiology insight.
22
And again, HCM was considered as increased force of contraction,
23
while DCM was decreased force of contraction with some elegant studies by the Potter group.
24
And then this was coupled to tension
25
and calcium transients with increased calcium signaling associated with hypertrophic cardiomyopathy and also decreased with dilated cardiomyopathy.
26
Now, what we understand are some of the genetic underpinnings of these principal findings that have been driven by population -based findings,
27
and I'll come back to those at the end of the talk.
28
So, you know that HCM gene ontology is shown here, these sarcomere genes.
29
If you can find genetic cause, about 80 % will be these two genes, MYH7 and MYBBC3.
30
And then if you add the troponins and trypomycin, you will get almost 95 % to 98 % of genetic cause,
31
adding in cardiac actin, the light chains.
32
You'll then get almost all of what you can find for at least conventional non -syndromic hypertrophic cardiomyopathy.
33
So hypertrophic cardiomyopathy is considered to be a genetic disease of sarcomeric proteins.
34
Let me comment on ClinGen, the Clinical Genome Resource.
35
It's a National Human Genome Research Institute resource.
36
I was very privileged to be chair of the Cardiovascular Clinical Domain Working Group.
37
My job was to, with others, to assemble numerous international groups of experts and then to do phenotyping for cardiomyopathies, channelopathies, aortopathies, and FH.
38
And the effort was to do structured gene and variant curations.
39
And I, again, was privileged to be part of a HCM gene curation.
40
And genes with published data for HCM were systematically scored on both clinical genetics evidence as well as laboratory and experimental evidence.
41
This was published at the Clinical Genome website and also the Ingalls et al.
42
CERC genetics medicine paper in 2019.
43
So these are the results of the ClinGen HCM gene curation as shown.
44
And this is all of the genes that were screened.
45
Let me break this down.
46
Let me point out that the blue is the experimental evidence and the pinkish red is the genetic evidence.
47
And let me drill down on the definitive, strong, and moderate genes.
48
There were eight definitive and strong evidence genes as shown here.
49
The key players, again, I will not repeat them, but you can see them.
50
And then interestingly, and you can see that the genetic evidence was really very strong, the majority of the evidence.
51
There was actually probably more experimental evidence, but after we hit the maximum number of points, we actually stopped curating.
52
And as you know, that these HCM genes have been around for a long time, so extensive experimental evidence.
53
Interestingly, three moderate evidence genes, CSRP3, troponin C1, and junk to fill in JPH2.
54
We're also considered moderate evidence genes with a fair amount of genetic evidence and also some experimental evidence,
55
and we consider that these 11 are the relevant genes for clinical genetic testing of hypertrophic cardiomyopathy.
56
There were also 16 limited evidence genes as shown here.
57
We consider these genes of uncertain significance or GUSs, and GUSs are less useful for genetic testing because a GUS is only able,
58
in unusual circumstances, to help with a variant classified as pathogenic or likely pathogenic.
59
And at least in the United States, using or applying American College of Medical Genetics guidelines,
60
only path or likely path variants are recommended for predictive testing of at -risk family members.
61
So even though these are interesting genes, and you can see there's actually a fair amount more of experimental data rather than genetic information.
62
We simply need more families, more individuals with testing with high quality published data to take
63
these forward to turn them into the next higher levels of evidence.
64
A few comments here on the ClinGen web interface that can be extremely useful shown here is MYPPC3.
65
You can see that hypertrophic cardiomyopathy is definitive for MYPPC3,
66
but only limited for ARVC or for dilated cardiomyopathy.
67
And again, this can be quite helpful.
68
And if you drill down into the website, you can see the key references.
69
This has all been extensively reviewed and vetted with, again, this international committee.
70
So again, quite helpful.
71
The experimental data also, all the references are shown there and how the scoring was done.
72
And then I think it's especially helpful with these limited evidence genes, particularly if there is a movement in the field or in the literature,
73
you can keep track of this.
74
ClinGen does plan to re -curate these every two to three years.
75
So Titan will come up for recuration probably in the next year.
76
Again, for hypertrophic cardiomyopathy, quite limited evidence, but quite interesting.
77
And again, it summarizes all the genetic experimental evidence with the key references.
78
So let me move on to genetic testing sensitivity.
79
Testing sensitivity is the probability that someone with a phenotype of interest will have a relevant variant.
80
And now we will call a relevant variant, one that is pathogenic or likely pathogenic.
81
That is greatly dependent upon the cohort characteristics, and it ranges as shown here from 63 % to 26%,
82
although I think these are quite representative reports over time.
83
I won't go through these in detail, but you can see from France, the Mayo Clinic series, Toronto series,
84
an Australian series, and then a couple of US series here.
85
I would comment that the Hathaway,
86
this last reference of almost 1 ,400 subjects had only 26 % sensitivity.
87
I'm going to drill down on that and give a bit more information.
88
But I would notably, this is the, I think, a representative commercial laboratory, at least in the U .S.
89
It's the only report that is using the American College of Medical Genetics 2015 classification.
90
And additional data I'll present again.
91
So the Richards et al genetic medicine classification is really quite stringent and quite conservative.
92
So some of this lower number may actually reflect that.
93
So the factors predicting positive testing in the Toronto series, They assessed clinical and echocardiographic variables and found that females,
94
thicker LV septum, positive family history, and morphology were positives.
95
If someone was hypertensive or older, they were less likely to have positive testing.
96
The Australian series replicated that, positive family history, and a positive family history of early sudden cardiac death,
97
and also by multivariate analysis and earlier age, female greater LV wool thickness, positive FH, and then FH of sudden early death.
98
This is a report from the Mayo Clinic from 2006 that shows a clinical phenotype by echocardiography pattern of 382 unrelated patients.
99
The frequency of each type is shown with sigmoid at 47 % shown here,
100
the reverse curve, what I think of as the classic pattern, 35%, apical 10%, and neutral 8%.
101
The genetic testing results are shown here, only 8 % for the sigmoid with by far the most genetic testings.
102
positive in the reverse curve, or this classic phenotype, 30 % of genetic testing, and I apologize you can't see this,
103
but it's a 10 % for the neutral.
104
The diagnostic yield of genetic testing in this report from the Hathaway et al is shown here.
105
There were this 26 .8 % were positive.
106
The clinical features associated with positive testing, again, younger age, increased ventricular wall thickness, positive family history, and absence of hypertension.
107
Let me show you the specific data.
108
Here you can see the frequency of HEM genes identified, and this is pretty much what the literature has shown really for the last 20 years.
109
MYBPC3 being the most common, MYH7 next close to 30%,
110
tropomycin next, the TNNI3, and then here's JPH2, troponin T, and then some syndromic genes.
111
I'll comment on that later.
112
The HCM genes were identified by ClinGen classification.
113
Almost all of the positives were in these definitive genes, those 11 that I showed before.
114
And then the next most common group are definitive syndromic genes.
115
The syndromic genes are shown here in the second line.
116
I won't go through those in detail.
117
And then, but very few, only 1 % of those limited genes.
118
And then testing sensitivity decreases with older age diagnosis.
119
Again, this recapitulates prior studies, and then also increases with wall thickness shown.
120
Let me comment on metabolic or infiltrative disease.
121
Three unusual, actually rare syndromes, PRK -AG2.
122
This HCM with WPW is very rare.
123
GLA -alpha -galactosidase causes Fabray disease, X -linked, rare but not as rare, something that we occasionally do see in clinical practice.
124
And then Dana disease from LAMP2, X -linked, and again, very rare.
125
So Fabray disease, just a couple of comments, predominantly is seen in male children and adolescents with a variety of systemic features,
126
acroparesthesias, angiokeratomas, renal and other findings.
127
The cardiovascular findings are concentric LVH, some angina, some valvular insufficiency.
128
And then it's this hypertrophic phenotype without obvious cause is the tip off.
129
The diagnosis is by plasma alpha galactosidase activity.
130
Of course, you can do genetic testing, and this is angiokeratomas, and I show you a close -up of this
131
if you see these just as a tip -off that this could be Fabray.
132
Let me finish with common genetic variants and modifiable risk factors,
133
a very interesting and key recent publication in Nature Genetics earlier this year.
134
This is from a U .S.
135
hypertrophic cardiomyopathy registry of over 2 ,500 cases and a U .K bioresource of 239 sarcomere -negative HCM patients.
136
So the principal approach was a genome -wide association study of these almost 2 ,800 cases.
137
Interestingly, two -thirds were sarcomere -negative.
138
That means negative genetic testing they identified 12 susceptibility loci with strong polygenic influence, especially in the sarcomerinegative group.
139
The findings are summarized here.
140
Common variants and clinical factors they found played key roles in HCM risk
141
and a genetic risk score influence odds of HCM with diastolic blood pressure being the key risk factor found,
142
especially in these sarcomerinegative patients.
143
And then one standard deviation increase in diastolic blood pressure increased HCM risk by fourfold.
144
This is really quite, quite remarkable.
145
I do anticipate a clinically deployed polygenic risk score to integrate rare and common variant genetics sometime soon.
146
Let me drill down and show you just a quick comment on some of the selected loci that were found.
147
These are neuter genes we recognize, HSPB7, phospholamban, BAG3, ALPK3, and FOD3.
148
These are genes that are also relevant and have been identified in dilated cardiomyopathy GWAS,
149
and it really illustrates the overlap or the interaction of DCM and HCM,
150
where they're really kind of tugging at each other to move the myocardium from hypocontractal to hypercontractal
151
and other probably more fundamental cellular processes.
152
Let me finish with this slide, which shows this key diastolic pressure finding.
153
The blue here is a sarcomere negative patients.
154
The orange are the sarcomere positive or genetic testing positive patients.
155
This is diastolic blood pressure, systolic blood pressure here, body mass index, and down here is type 2 diabetes.
156
So you can see the striking finding is this diastolic blood pressure.
157
Okay, I am at 15 minutes now.
158
And just to summarize, HCM is a genetic disease of sarcomere proteins.
159
Rare variants of sarcomere genes drive heritable familial HCM, which is amenable to testing.
160
With an HCM diagnosis, genetic testing is indicated to clarify etiology, assess family risk, and inform possible treatment options.
161
And then common variants also contribute to HCM phenotype, especially for those with negative genetic testing.
162
And then I suspect we'll have polygenic risk scores incorporating common variants and rare variants for HCM to emerge probably this decade.
163
Again, I would like to thank the organizers for the opportunity to present, and I will stop and turn it back over to the chair.
164
Thank you very much.

ดาวน์โหลดแอป

ทุกอย่างที่ต้องใช้เพื่อพูดได้คล่อง

AI ให้คะแนนการออกเสียงให้คะแนนทุกประโยค
ฝึก IPAเชี่ยวชาญทุกเสียง
คำศัพท์สร้างคลังคำของคุณ
เกมคำศัพท์เล่นไปเรียนไป
FOR YOU

วิดีโอแนะนำ

คำศัพท์และข้อสังเกตด้านการพูดสำหรับบทเรียนนี้

บทเรียนฝึกพูดนี้ใช้วิดีโอ “Genetics of Hypertrophic Cardiomyopathy” เป็นสื่อ คำที่ถูกพูดซ้ำบ่อยที่สุด: genetic, gene, Hcm, testing, evidence วิดีโอนี้มี 164 ประโยค และ 2161 คำ สำหรับฝึกพูดตาม ช่วงที่มีเสียงพูดยาว 16:18 ผู้พูดพูดด้วยความเร็วสม่ำเสมอ ประมาณ 133 คำต่อนาที เหมาะกับการฝึกพูดตาม มีเพียง 73% ของคำที่อยู่ใน 3,000 คำที่ใช้บ่อยที่สุดในภาษาอังกฤษ คำศัพท์จึงค่อนข้างยาก

คำศัพท์สำคัญในวิดีโอนี้

คำที่ควรเรียนรู้ 15 คำจากวิดีโอ พร้อมคำอ่านและความหมาย:

คำศัพท์คำอ่านความหมาย
gene คำนาม/d͡ʒiːn/หน่วยพันธุกรรม
variant คำนาม/ˈvæɹi.ənt/การเปลี่ยนแปลง
genetics คำนาม/dʒəˈnɛt.ɪks/พันธุศาสตร์
drill คำนาม/dɹɪl/สว่าน
thick คำคุณศัพท์/θɪk/หนา
moderate คำคุณศัพท์/ˈmɑdəɹət/ปานกลาง, พอประมาณ
diagnosis คำนาม/daɪəɡˈnəʊsɪs/การวินิจฉัย
thickness คำนาม/ˈθɪknəs/ความหนา
thin คำคุณศัพท์/ˈθɪn/บาง
sudden คำคุณศัพท์/ˈsʌd.ən/กะทันหัน
resource คำนาม/ɹɪˈzɔːs/ทรัพยากร
frequency คำนาม/ˈfɹiːkwənsi/ความถี่
laboratory คำนาม/ˈlæb(ə)ɹəˌtɔɹi/ห้องปฏิบัติการ
alpha คำนาม/ˈæl.fə/แอลฟา
neutral คำคุณศัพท์/ˈnuː.tɹəl/เป็นกลาง

ไวยากรณ์ในวิดีโอนี้

โครงสร้างที่ผู้พูดใช้บ่อยที่สุด พร้อมคำพูดจริงจากวิดีโอ:

โครงสร้างในวิดีโอ
Passive voice be + กริยาช่อง 3 — เน้นสิ่งที่เกิดขึ้น ไม่ใช่ผู้กระทำwas considered · was decreased · was coupled
Present perfect have/has + กริยาช่อง 3 — เหตุการณ์ในอดีตที่ยังเกี่ยวข้องกับปัจจุบันhas shown · We've really learned · have been driven
Relative clauses who / which + อนุประโยค — ข้อมูลเพิ่มเติมเกี่ยวกับคนหรือสิ่งของone that is · HCM, which is

การออกเสียงที่ควรระวัง

ผู้พูดใช้รูปย่อและรูปลดเสียง 13 ครั้ง เช่น I'll, won't, can't ให้พูดแบบสั้นตามที่ได้ยิน

  • เสียง “th”: thick /θɪk/, thickness /ˈθɪknəs/, thin /ˈθɪn/, pathogenic /pæθəˈd͡ʒɛnɪk/
  • เสียง “sh” และ “zh”: classification /ˌklæsɪfɪˈkeɪʃən/, unusual /ʌnˈjuːʒ(u)əl/, publication /ˌpʌblɪˈkeɪʃ(ə)n/, occasionally /əˈkeɪʒənəli/, interaction /ˌɪn.təˈɹæk.ʃən/
  • คำยาว — ลงเสียงหนักให้ถูกพยางค์: experimental /ɪkspɛɹəˈmɛntəl/, definitive /dɪˈfɪn.ɪ.tɪv/, sensitivity /ˌsɛn.səˈtɪv.ə.ti/, classification /ˌklæsɪfɪˈkeɪʃən/, cardiovascular /ˌkɑːdi.əʊˈvæskjʊlə(ɹ)/

เสียงที่คนไทยมักออกเสียงยาก:

  • เสียงท้ายคำ — ออกเสียงให้ครบ ไม่เปลี่ยนเป็นตัวสะกดแบบไทย: experimental /ɪkspɛɹəˈmɛntəl/, genetics /dʒəˈnɛt.ɪks/, definitive /dɪˈfɪn.ɪ.tɪv/, drill /dɹɪl/, diagnosis /daɪəɡˈnəʊsɪs/
  • /v/ — ไม่ใช่ /w/ ให้ฟันบนแตะริมฝีปากล่าง: variant /ˈvæɹi.ənt/, definitive /dɪˈfɪn.ɪ.tɪv/, sensitivity /ˌsɛn.səˈtɪv.ə.ti/, cardiovascular /ˌkɑːdi.əʊˈvæskjʊlə(ɹ)/, reverse /ɹɪˈvɝs/
  • /z/ — เสียงก้อง ไม่ใช่ /s/: resource /ɹɪˈzɔːs/, organizer /ˈɔɹɡənaɪzɚ/, diabetes /ˌdaɪəˈbiːtiːz/, apologize /əˈpɑləˌd͡ʒaɪz/, plasma /ˈplæzmə/

วิธีฝึกกับวิดีโอนี้

  1. ฟังวิดีโอให้จบหนึ่งรอบโดยยังไม่ต้องพูด แล้วจดคำที่ยังไม่รู้จัก
  2. พูดตามทีละประโยคด้วยความเร็วปกติ ทำซ้ำแต่ละประโยคจนจังหวะของคุณตรงกับผู้พูด
  3. อัดเสียงตัวเองแล้วเทียบกับต้นฉบับ โดยสังเกตคำอย่าง gene, variant, genetics เป็นพิเศษ

เทคนิค Shadowing คืออะไร?

Shadowing เป็นเทคนิคการเรียนรู้ภาษาที่ได้รับการรับรองทางวิทยาศาสตร์ พัฒนาขึ้นสำหรับการฝึกนักแปลมืออาชีพ วิธีการนี้เรียบง่ายแต่ทรงพลัง: คุณฟังเสียงภาษาอังกฤษจากเจ้าของภาษาและพูดตามทันที — เหมือนเงาที่ตามผู้พูดด้วยช่วงเวลาห่าง 1-2 วินาที การวิจัยแสดงว่าเทคนิคนี้ปรับปรุงความแม่นยำในการออกเสียง ทำนองเสียง จังหวะ การเชื่อมเสียง การฟังเข้าใจ และความคล่องแคล่วในการพูดได้อย่างมีนัยสำคัญ

เทคนิค shadowing: อ่านคู่มือฉบับเต็มทีละขั้นตอน →